FDA approves Opdivo for initial treatment of advanced gastrointestinal cancers

FDA approves Opdivo for initial treatment of advanced gastrointestinal cancers

The FDA approved nivolumab as part of combination therapy for certain patients with gastrointestinal malignancies.The approval applies to use of the agent with certain types of chemotherapy as initial treatment for advanced or metastatic gastric cancer, gastroesophageal junction cancer or esophageal adenocarcinoma.Nivolumab (Opdivo, Bristol Myers Squibb) — a PD-1 inhibitor approved in the United States for treatment of several cancer types — is the first immunotherapy approved for first-line treatment of gastric cancer.An estimated 28,000 new cases of gastric cancer are diagnosedRead More

Share on facebook
Share on twitter
Share on linkedin